Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Chubb
Baxter
Johnson and Johnson
Harvard Business School
Federal Trade Commission
McKinsey
Cipla
Covington

Generated: May 22, 2018

DrugPatentWatch Database Preview

ZEMURON Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Zemuron patents expire, and what generic alternatives are available?

Zemuron is a drug marketed by Organon Usa Inc and is included in one NDA.

The generic ingredient in ZEMURON is rocuronium bromide. There are eleven drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the rocuronium bromide profile page.
Summary for ZEMURON
Drug patent expirations by year for ZEMURON
Synonyms for ZEMURON
(2beta,3alpha,5alpha,16beta,17beta)-17-(acetyloxy)-3-hydroxy-2-morpholin-4-yl-16-(1-prop-2-en-1-ylpyrrolidinium-1-yl)androstane bromide
[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-16-(1-allylpyrrolidin-1-ium-1-yl)-3-hydroxy-10,13-dimethyl-2-morpholino-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate bromide
[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate bromide
1-((2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetoxy-3-hydroxy-10,13-dimethyl-2-morpholinohexadecahydro-1H-cyclopenta[a]phenanthren-16-yl)-1-allylpyrrolidin-1-ium bromide
1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-14-(ACETYLOXY)-5-HYDROXY-2,15-DIMETHYL-4-(MORPHOLIN-4-YL)TETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECAN-13-YL]-1-(PROP-2-EN-1-YL)PYRROLIDIN-1-IUM BROMIDE
1-[(2B,3A,5A,16B,17B)-17-(ACETYLOXY)-3-HYDROXY-2-(4-MORPHOLINYL)ANDROSTAN-16-YL]-1-(2-PROPENYL)PYRROLIDINIUM BROMIDE
1-[(2beta,3alpha,5alpha,16beta,17beta)-17-acetyloxy-3-hydroxy-2-(4-morpholinyl)-androstan-16-yl]-1(2-propenyl)pyrrolidinium bromide
1-[17B-(ACETYLOXY)-3A-HYDROXY2B-(4-MORPHOLINYL)-5A-ANDROSTAN-16B-YL]-1-(2-PROPENYL)PYRROLIDINIUM BROMIDE
1-[17BETA-(ACETYLOXY)-3ALPHA-HYDROXY-2BETA-(4-MORPHOLINYL)-5ALPHA-ANDROSTAN-16BETA-YL]-1-(2-PROPENYL)PYRROLIDINIUM BROMIDE
1-[17beta-acetyloxy-3alpha-hydroxy-2beta-(4-morpholinyl)-5alpha-androstan-16beta-yl]-1-(2-propenyl)pyrrolidinium bromide
1-Allyl-1-(3alpha,17beta-dihydroxy-2beta-morpholino-5alpha-androstan-16beta-yl)pyrrolidinium bromide, 17-acetate
111GE014
119302-91-9
17beta-(acetyloxy)-3alpha-hydroxy-2beta-(morpholin-4-yl)-16beta-[1-(prop-2-en-1-yl)pyrrolidinium-1-yl]-5alpha-androstane
17beta-acetoxy-16beta-(1-allylpyrrolidinium-1-yl)-3alpha-hydroxy-2beta-(morpholin-4-yl)-5alphaandrostane
AC-2004
AC1L9B0Y
AKOS025149635
AN-14416
API0024407
AS-13323
BC004036
BC222603
BCP0726000028
BROMOROCURONIUM
C-23335
CAS-119302-91-9
CC-34280
cc-624
CHEBI:8885
CHEMBL1200648
CR-015
CR0018
CS-1467
D00765
DR003367
DSSTox_CID_3566
DSSTox_GSID_23566
DSSTox_RID_77083
DTXSID7023566
Eslax
Esmeron
HY-17440
I65MW4OFHZ
NCGC00167433-01
ORG 9426
Org-9426
org9426
OYTJKRAYGYRUJK-FMCCZJBLSA-M
PL042932
PubChem15778
Pyrrolidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl)-1-(2-propenyl)-, bromide
Q-101010
R0099
Rocuroium Bromide
Rocuronium (Bromide)
ROCURONIUM BROMIDE
Rocuronium bromide (JAN/USAN/INN)
Rocuronium bromide [USAN:USP:INN:BAN]
Rocuronium bromide, >=98% (perchloric acid titration)
Rocuronium bromide, European Pharmacopoeia (EP) Reference Standard
Rocuronium bromide, United States Pharmacopeia (USP) Reference Standard
Rocuronium for peak identification, European Pharmacopoeia (EP) Reference Standard
Rocuroniun bromide
s1397
SC-21811
SCHEMBL41320
ST24049126
Tox21_112437
UNII-I65MW4OFHZ
W-5167
Zemuron (TN)

US Patents and Regulatory Information for ZEMURON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon Usa Inc ZEMURON rocuronium bromide INJECTABLE;INJECTION 020214-001 Mar 17, 1994 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Organon Usa Inc ZEMURON rocuronium bromide INJECTABLE;INJECTION 020214-002 Mar 17, 1994 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Organon Usa Inc ZEMURON rocuronium bromide INJECTABLE;INJECTION 020214-003 Mar 17, 1994 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for ZEMURON

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Organon Usa Inc ZEMURON rocuronium bromide INJECTABLE;INJECTION 020214-003 Mar 17, 1994 ➤ Sign Up ➤ Sign Up
Organon Usa Inc ZEMURON rocuronium bromide INJECTABLE;INJECTION 020214-001 Mar 17, 1994 ➤ Sign Up ➤ Sign Up
Organon Usa Inc ZEMURON rocuronium bromide INJECTABLE;INJECTION 020214-002 Mar 17, 1994 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Fish and Richardson
Merck
Deloitte
Covington
Queensland Health
Johnson and Johnson
Chinese Patent Office
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.